SCHEMBL777824

SCHEMBL777824

O=C(Oc1ccc2cc(OC(=O)c3ccc(O)cc3)ccc2c1)c1ccc(O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 9/20 0.65
▸ MEN1 O00255 6/20 0.65
▸ MAPT P10636 2/20 0.65
▸ TDP1 Q9NUW8 1/20 0.65
▸ ESR1 P03372 4/20 0.56
▸ CASP3 P42574 2/20 0.55
▸ SENP8 Q96LD8 2/20 0.55
▸ SENP7 Q9BQF6 2/20 0.55
▸ SENP6 Q9GZR1 2/20 0.55
▸ HGFAC Q04756 2/20 0.51
▸ TMPRSS2 O15393 1/20 0.51
▸ MLNR O43193 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ F2 P00734 1/20 0.51
▸ C1R P00736 1/20 0.51
▸ F10 P00742 1/20 0.51
▸ PLG P00747 1/20 0.51
▸ F12 P00748 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ ITGB3 P05106 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8756308 0.96 KMT2A (0.61) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL11297653 0.96 KMT2A (0.61) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL8851038 0.93 KMT2A (0.77) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL9793342 0.91 KMT2A (0.60) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL14679430 0.91 KMT2A (0.63) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL8461218 0.89 KMT2A (0.58) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL23386312 0.89 KMT2A (0.66) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL12859553 0.89 KMT2A (0.66) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL14373622 0.88 KMT2A (0.53) KMT2AMEN1MAPTTDP1ESR1
SCHEMBL4124502 0.88 KMT2A (0.57) KMT2AMEN1MAPTTDP1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067772-A1 EPOXY COMPOUND, COMPOSITION PREPARED THEREFROM, SEMICONDUCTOR DEVICE PREPARED THEREFROM, ELECTRONIC DEVICE PREPARED THEREFROM, ARTICLE PREPARED THEREFROM, AND METHOD OF PREPARING EPOXY COMPOUND SAMSUNG ELECTRONICS CO LTD (KR) 2024-02-29 — — US disclosed
US-20240067772-A1 EPOXY COMPOUND, COMPOSITION PREPARED THEREFROM, SEMICONDUCTOR DEVICE PREPARED THEREFROM, ELECTRONIC DEVICE PREPARED THEREFROM, ARTICLE PREPARED THEREFROM, AND METHOD OF PREPARING EPOXY COMPOUND SAMSUNG ELECTRONICS CO LTD (KR) 2024-02-29 — — US disclosed
US-11827741-B2 Epoxy compound, composition prepared therefrom, semiconductor device prepared therefrom, electronic device prepared therefrom, article prepared therefrom, and method of preparing epoxy compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-11-28 — — US disclosed
US-11827741-B2 Epoxy compound, composition prepared therefrom, semiconductor device prepared therefrom, electronic device prepared therefrom, article prepared therefrom, and method of preparing epoxy compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-11-28 — — US disclosed
US-20220185947-A1 EPOXY COMPOUND, COMPOSITION PREPARED THEREFROM, SEMICONDUCTOR DEVICE PREPARED THEREFROM, ELECTRONIC DEVICE PREPARED THEREFROM, ARTICLE PREPARED THEREFROM, AND METHOD OF PREPARING EPOXY COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2022-06-16 — — US disclosed
US-8404794-B2 Liquid crystal compositions E I DU PONT DE NEMOURS AND COMPANY (US) 2013-03-26 — — US disclosed
US-8404794-B2 Liquid crystal compositions E I DU PONT DE NEMOURS AND COMPANY (US) 2013-03-26 — — US disclosed
US-8404316-B2 Polymerizable liquid crystal compound and its polymer JNC CORPORATION (JP) 2013-03-26 — — US disclosed
US-8344175-B2 Liquid crystal compositions, polymer networks derived therefrom and process for making the same E I DU PONT DE NEMOURS AND COMPANY (US) 2013-01-01 — — US disclosed
US-8344175-B2 Liquid crystal compositions, polymer networks derived therefrom and process for making the same E I DU PONT DE NEMOURS AND COMPANY (US) 2013-01-01 — — US disclosed
US-7879256-B2 bis(meth)acrylates with esters linking mesogen to a flexible spacer and polymerizable (meth)acrylates E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-02-01 — — US disclosed
US-7879256-B2 bis(meth)acrylates with esters linking mesogen to a flexible spacer and polymerizable (meth)acrylates E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-02-01 — — US disclosed
US-20100308265-A1 LIQUID CRYSTAL COMPOSITIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308265-A1 LIQUID CRYSTAL COMPOSITIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308268-A1 LIQUID CRYSTAL COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308269-A1 LIQUID CRYSTAL COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308269-A1 LIQUID CRYSTAL COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308270-A1 LIQUID CRYSTAL COMPOSTIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308270-A1 LIQUID CRYSTAL COMPOSTIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed
US-20100308268-A1 LIQUID CRYSTAL COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100308265-A1 LIQUID CRYSTAL COMPOSITIONS CNOT9, AQP3, AQP1 KMT2A 3598/4885MEN1 1865/4885MAPT 23/4885
US-20100308270-A1 LIQUID CRYSTAL COMPOSTIONS TTR, CNOT9, CNOT7 KMT2A 3298/4885MEN1 333/4885MAPT 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback